Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(5):684–689. doi: 10.1038/bjc.1997.122

Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue.

M Diez 1, M Pollán 1, M Maestro 1, A Torres 1, D Ortega 1, A Gómez 1, A Sánchez 1, F Hernando 1, J L Balibrea 1
PMCID: PMC2063350  PMID: 9043025

Abstract

The concentration of c-erbB-2 oncogene-encoded protein (p185neu) in fresh tumour samples obtained at the time of surgery from 94 non-small-cell lung cancer patients (NSCLC) was determined by an enzyme immunoassay. The relative prognostic importance was estimated, and the influence of other predictors was assessed by means of a Cox's proportional regression model. Median concentration of p185 in tumour tissues was 206 U mg(-1) (range 21-1050 U mg(-1)). p185 level did not differ significantly among subgroups defined by TNM classification, histological type, sex and age. Categorization of patients by p185 level, with 206 U mg(-1) and 343 U mg(-1) taken as cut-off values (corresponding to the 50th and 80th percentiles of the frequency distribution), showed that the recurrence rate, cumulative disease-free likelihood at the 36-month follow-up and median time from surgery to the diagnosis of recurrence worsened progressively as the level of p185 increased. Multivariate analysis confirmed the independent prognostic value of p185 level. Risk of recurrence increased by 1.304 for every increase of 100 units in p185 concentration (95% CI 1.141-1.490) (P<0.001). These findings encourage the inclusion of p185 concentration assay in a future predictive multifactorial prognostic index in NSCLC.

Full text

PDF
684

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bongiorno P. F., Whyte R. I., Lesser E. J., Moore J. H., Orringer M. B., Beer D. G. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J Thorac Cardiovasc Surg. 1994 Feb;107(2):590–595. [PubMed] [Google Scholar]
  2. Coussens L., Yang-Feng T. L., Liao Y. C., Chen E., Gray A., McGrath J., Seeburg P. H., Libermann T. A., Schlessinger J., Francke U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985 Dec 6;230(4730):1132–1139. doi: 10.1126/science.2999974. [DOI] [PubMed] [Google Scholar]
  3. Cuny M., Simony-Lafontaine J., Rouanet P., Grenier J., Valles H., Lavaill R., Louason G., Causse A., Lequeux N., Thierry C. Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations. Oncol Res. 1994;6(4-5):169–176. [PubMed] [Google Scholar]
  4. Dittadi R., Donisi P. M., Brazzale A., Marconato R., Spina M., Gion M. Immunoenzymatic assay of erbB2 protein in cancer and non-malignant breast tissue. Relationships with clinical and biochemical parameters. Anticancer Res. 1992 Nov-Dec;12(6B):2005–2010. [PubMed] [Google Scholar]
  5. Drebin J. A., Stern D. F., Link V. C., Weinberg R. A., Greene M. I. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature. 1984 Dec 6;312(5994):545–548. doi: 10.1038/312545a0. [DOI] [PubMed] [Google Scholar]
  6. Fielding L. P., Fenoglio-Preiser C. M., Freedman L. S. The future of prognostic factors in outcome prediction for patients with cancer. Cancer. 1992 Nov 1;70(9):2367–2377. doi: 10.1002/1097-0142(19921101)70:9<2367::aid-cncr2820700927>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  7. Fukushige S., Matsubara K., Yoshida M., Sasaki M., Suzuki T., Semba K., Toyoshima K., Yamamoto T. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol. 1986 Mar;6(3):955–958. doi: 10.1128/mcb.6.3.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Harpole D. H., Jr, Herndon J. E., 2nd, Wolfe W. G., Iglehart J. D., Marks J. R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995 Jan 1;55(1):51–56. [PubMed] [Google Scholar]
  9. Kern J. A., Schwartz D. A., Nordberg J. E., Weiner D. B., Greene M. I., Torney L., Robinson R. A. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990 Aug 15;50(16):5184–5187. [PubMed] [Google Scholar]
  10. Kern J. A., Slebos R. J., Top B., Rodenhuis S., Lager D., Robinson R. A., Weiner D., Schwartz D. A. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest. 1994 Feb;93(2):516–520. doi: 10.1172/JCI117001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. McKenzie S. J., Marks P. J., Lam T., Morgan J., Panicali D. L., Trimpe K. L., Carney W. P. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene. 1989 May;4(5):543–548. [PubMed] [Google Scholar]
  12. Narita T., Funahashi H., Satoh Y., Imai T., Takagi H. Quantitative analysis of c-erbB-2 protein in breast cancer tissue by enzyme immunoassay. Jpn J Clin Oncol. 1994 Apr;24(2):74–78. [PubMed] [Google Scholar]
  13. Nugent A., Gallagher J., Dolan J., O'Higgins N., Duffy M. J. Assay of the c-erbB-2 oncogene encoded protein by ELISA and immunocytochemistry in human breast cancer. Ann Clin Biochem. 1994 Mar;31(Pt 2):171–173. doi: 10.1177/000456329403100210. [DOI] [PubMed] [Google Scholar]
  14. Shi D., He G., Cao S., Pan W., Zhang H. Z., Yu D., Hung M. C. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinog. 1992;5(3):213–218. doi: 10.1002/mc.2940050308. [DOI] [PubMed] [Google Scholar]
  15. Stern D. F., Heffernan P. A., Weinberg R. A. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol. 1986 May;6(5):1729–1740. doi: 10.1128/mcb.6.5.1729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tateishi M., Ishida T., Mitsudomi T., Kaneko S., Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer. 1991;27(11):1372–1375. doi: 10.1016/0277-5379(91)90012-3. [DOI] [PubMed] [Google Scholar]
  17. Tsai C. M., Yu D., Chang K. T., Wu L. H., Perng R. P., Ibrahim N. K., Hung M. C. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst. 1995 May 3;87(9):682–684. doi: 10.1093/jnci/87.9.682. [DOI] [PubMed] [Google Scholar]
  18. Weiner D. B., Nordberg J., Robinson R., Nowell P. C., Gazdar A., Greene M. I., Williams W. V., Cohen J. A., Kern J. A. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res. 1990 Jan 15;50(2):421–425. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES